Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.

The Journal of antimicrobial chemotherapy - 1 Feb 2015

Hesje C K, Drlica K, Blondeau J M

Abstract excerpt

BACKGROUND: The mutant prevention concentration (MPC) reflects the antimicrobial susceptibility of the resistant mutant subpopulations present in large bacterial populations. In principle, combining the MPC with pharmacokinetic measurements can guide treatment to restrict the enrichment of resistant subpopulations, just as the MIC is used with pharmacokinetics to restrict the growth of bulk, susceptible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microbial Sensitivity Tests

Share to Minocycline

Share to Mutation

Share to Staphylococcus aureus

Share to Streptococcus pneumoniae

Share to Tigecycline

Source

Open in PubMed Open full text

Identifiers

PMID: 25324419
DOI: 10.1093/jac/dku389
PMCID: PMC4291236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.PMID 25324419Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.Semantic proximity Read ↗

Comparison of Mutant Prevention Concentrations of Fluoroquinolones Against ESBL-Positive and ESBL-Negative Klebsiella pneumoniae Isolates from Orthopedic Patients.Semantic proximity Read ↗

Therapeutic options in an era of decreasing antimicrobial susceptibility.Semantic proximity Read ↗

Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.Semantic proximity Read ↗

Emergence and spread of antibiotic resistance following exposure to antibiotics.Semantic proximity Read ↗

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.Semantic proximity Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.